Revolutionary CAR T-cell therapy shows promise in reversing age-related metabolic dysfunction

Revolutionary CAR T-cell therapy shows promise in reversing age-related metabolic dysfunction - Blog

Cellular senescence is an irreversible cell cycle arrest induced in response to stress. Under stressful conditions, matrix remodeling enzymes and pro-inflammatory cytokines are produced, termed Senescence-Associated Secretory Phenotype (SASP). In young individuals with physiological conditions, such as tumor suppression and wound healing, SASP facilitates the recruitment of immune cells, which facilitate tissue restoration and the […]

Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial | Nature Medicine

Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial | Nature Medicine - Blog

Researchers have reported promising results in a Phase I/II trial involving 37 patients with relapsed or refractory B-cell malignancies who were treated with a cord blood-derived natural killer (NK) chimeric antigen receptor (CAR), a cell therapy targeting CD19. Results showed an overall response (OR) rate of 48.6% 100 days after treatment, with one-year progression-free survival […]

CRISPR-Based Anti-CD19 CAR T-Cell Therapy Is Safe and Effective in Relapsed/Refractory NHL

CRISPR-Based Anti-CD19 CAR T-Cell Therapy Is Safe and Effective in Relapsed/Refractory NHL - Blog

The CD19-directed, non-viral, PD-1 locus-specific, CRISPR-based integrated CAR T cell therapy BRL-201 was associated with a manageable safety profile and elicited early indications of efficacy in patients with relapsed and refractory non-Hodgkin’s lymphoma (NHL), according to results from a first-in-man Phase 1 trial (NCT04213469). No dose-limiting toxicity (DLT) was observed in any of the patient […]

Metabolically armored CAR-T cells demonstrate lasting efficacy against solid tumors

Metabolically armored CAR-T cells demonstrate lasting efficacy against solid tumors - Blog

Traditional CAR-T cells, while effective against liquid cancers, face challenges in solid tumors: the cells wear out and ultimately fail to destroy the cancer completely. Ground-breaking research is providing an innovative approach to this challenge. Researchers are introducing CAR-T cells that excrete the IL-10 molecule. In other words, the cell has been designed to produce […]

Prime- and base-editing mouse models advance cancer research

Prime- and base-editing mouse models advance cancer research - Blog

The landscape of cancer research is being transformed by the introduction of new mouse models using prime- and base-editing techniques. The prime-editing mouse model stands out for its high editing efficiencies, particularly in lung and pancreatic organoids. This model facilitates in-depth exploration of drug-resistance mutations, a critical aspect in cancer treatment. Similarly, the base-editing model […]

CAR-T cell therapy remains viable for patients in lymphoma remission, study finds

CAR-T cell therapy remains viable for patients in lymphoma remission, study finds - Blog

For some patients who receive cell therapy such as CAR-T cells, this comes after many other treatments have failed. Researchers noticed that their patients who received the cells while in remission tended to do well after their infusion. They proposed a research study to follow patients who had received a transplant and/or cell therapy. The […]

CRISPR screening unveils ATXN3 as a new cancer treatment target

CRISPR screening unveils ATXN3 as a new cancer treatment target - Blog

Using CRISPR screening, the deubiquitinase ATXN3 was identified as a key regulator of PD-L1 transcription in tumor cells, a critical factor in tumor immune evasion. In this study, researchers transfected a targeted library of all 96 members of the mammalian deubiquitinase family into melanoma cells, then sorted the cells according to low and high PD-L1 […]

Self-copying RNA vaccine wins first full approval: what’s next? – Nature

Self-copying RNA vaccine wins first full approval: what’s next? - Nature - Blog

The approval of yet another RNA-based vaccine for COVID-19 might not seem momentous. But the endorsement last week by Japanese authorities of a jab against SARS-CoV-2 constructed using a form of RNA that can make copies of itself inside cells — the first ‘self-amplifying’ RNA (saRNA) granted full regulatory approval anywhere in the world — marks a […]

St. Jude scientists discover potential CAR T cell therapy target for brain and solid tumors

St. Jude scientists discover potential CAR T cell therapy target for brain and solid tumors - Blog

L’une des difficultés qui a entravé le succès des cellules CAR-T dans les tumeurs cérébrales et solides est la difficulté d’identifier une bonne cible pour ces cancers. Cependant, les chercheurs ont découvert que GRP78 est une excellente cible pour les cellules CAR-T. Les chercheurs ont ensuite créé des cellules CAR-T ciblant GRP78 qui ont réussi […]

New approach to CAR T cell therapy may extend treatment effectiveness

New approach to CAR T cell therapy may extend treatment effectiveness - Blog

La tendance des cellules CAR-T à perdre leur fonction au fil du temps, un phénomène connu sous le nom d’épuisement des cellules T, a été un obstacle majeur au traitement. Même lorsque les cellules CAR-T sont efficaces à court terme, le cancer réapparaît souvent. Ce problème explique en partie pourquoi la thérapie par cellules CAR-T […]